Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Simcere Pharmaceutical Group's PB Ratio or its related term are showing as below:
STU:S2P'
s PB Ratio Range Over the Past 10 Years
Min: 1.7 Med: 2.98 Max: 16.9
Current: 3.18
During the past 9 years, Simcere Pharmaceutical Group's highest PB Ratio was 16.90. The lowest was 1.70. And the median was 2.98.
STU:S2P's PB Ratio is ranked worse than 70.58% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.87
vs STU:S2P: 3.18
During the past 12 months, Simcere Pharmaceutical Group's average Book Value Per Share Growth Rate was 32.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.60% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Simcere Pharmaceutical Group was 67.90% per year. The lowest was 0.20% per year. And the median was 27.05% per year.
Back to Basics: PB Ratio
Simcere Pharmaceutical Group (STU:S2P) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Simcere Pharmaceutical Group PB Ratio Related Terms
Simcere Pharmaceutical Group PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Simcere Pharmaceutical Group (STU:S2P) has a PB Ratio of 3.14 as of Jul. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Simcere Pharmaceutical Group and its competitors. This is near median its historical median of 2.98. Over the past decade, Simcere Pharmaceutical Group's PB Ratio has ranged from 1.70 to 16.90. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #650 out of 921 companies in the Drug Manufacturers industry, placing it in the top 70.6%.
Is Simcere Pharmaceutical Group's PB Ratio too high?
Simcere Pharmaceutical Group's current PB Ratio of 3.14 is near median its 10-year median of 2.98. Over the past 10 years, this metric has ranged from a low of 1.70 to a high of 16.90. The Drug Manufacturers industry median PB Ratio is 1.87. Simcere Pharmaceutical Group's value of 3.14 is 67.9% above this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #650 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #650 out of 921 companies for PB Ratio. This places Simcere Pharmaceutical Group in the lower half of its industry. The industry median PB Ratio is 1.87. Simcere Pharmaceutical Group's value of 3.14 is 67.9% above this benchmark. Historically, Simcere Pharmaceutical Group's own PB Ratio has ranged from 1.70 to 16.90 over the past decade. While the company's 10-year median is 2.98 vs. the industry median of 1.87, Simcere Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.87, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current PB Ratio of 3.14 is 67.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current PB Ratio is 3.14, which is near median its own 10-year median of 2.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Simcere Pharmaceutical Group (STU:S2P) has a current PB Ratio of 3.14. The stock's GF Value™ is €1.16, compared to a current price of €1.38 — trading 19% above its estimated fair value. The current PB Ratio is 3.14, which is near median its 10-year median of 2.98 and 67.9% above the Drug Manufacturers industry median of 1.87. Simcere Pharmaceutical Group's overall GF Score™ is 94/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Simcere Pharmaceutical Group (STU:S2P), the current PB Ratio is 3.14 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (STU:S2P) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.38 is trading 19% above its estimated GF Value™ of €1.16.
Key valuation signals for STU:S2P:
PB Ratio: 3.14 (near median its 10-year median of 2.98)
GF Value™: €1.16 vs. price of €1.38 (19% above fair value)
Industry Position: 67.9% above the Drug Manufacturers median (#650 of 921)
No single metric tells the full story. See the STU:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
94GF Score
Get the complete analysis for STU:S2P
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:S2P has been successfully added to your 
